ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ivonescimab

Also written as “AK112”, “Ivonescimab Injection” and “Ivonescimab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma, led by 5 companies.

Drug pageIvonescimab: every studyMany companies study it; this page follows only the 48 they lead. All 147 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 21, 202148 company-led studies, 39 open or runningLicense: Akeso → Summit Therapeutics, Dec 2022Next primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso3930 open or runningphase 3since Dec 21, 2021Aug 5, 2019Dec 2026phase 2 · NCT05689853
Summit Therapeuticsits history only66 open or runningphase 3since Jun 1, 2023Jun 1, 2023Apr 2028phase 3 · NCT06767514
GlaxoSmithKlineits history only11 open or runningphase 2since May 15, 2026May 15, 2026Jun 22, 2029phase 2 · NCT07602855
Multitude Therapeuticsits history only11 open or runningphase 2since May 10, 2026May 10, 2026May 30, 2027phase 2 · NCT07590531
Shanghai Allink Biotherapeuticsits history only11 open or runningphase 2since Jul 29, 2026Jul 29, 2026Dec 31, 2027phase 2 · NCT07742956

Also a collaborator on its studies: Shanghai Virogin Biotech.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How GlaxoSmithKline, Multitude Therapeutics and Shanghai Allink Biotherapeutics relate to it is not in the registry or these sources.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 22 earlier studies, Aug 5, 2019 to Jul 28, 2024.

  1. Jul 28, 2021Named ivonescimabINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AK112
  2. Dec 6, 2022Summit Therapeutics licensed it from AkesoLicenseThe US, Canada, Europe and Japan · announced · Summit Therapeutics (8-K exhibit)
  3. Aug 15, 2024Phase 2 study in Ovarian NeoplasmsNCT06560112 · 172 planned · China
  4. Aug 29, 2024Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06601335 · 510 planned · China
  5. Sep 8, 2024Phase 3 study in Biliary Tract NeoplasmsNCT06591520 · 682 enrolled · China
  6. Oct 16, 2024Phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055 · 110 enrolled · China
  7. Nov 11, 2024Phase 2 study in Platinum-sensitive Ovarian CancerNCT06686030 · 150 planned · China
  8. Jan 8, 2025Phase 3 study in Triple Negative Breast NeoplasmsNCT06767527 · 416 planned · China
  9. Mar 10, 2025Phase 2 study in Biliary Tract NeoplasmsNCT06938321 · 135 planned · China
  10. Apr 8, 20253 phase 3 studiesNCT06928389, NCT06951503, NCT06953999
  11. May 25, 2025Phase 3 study in Small Cell Lung CarcinomaNCT07010263 · 560 planned · China
  12. Aug 3, 20252 phase 2 studiesNCT07114315, NCT07158840
  13. Sep 29, 2025Phase 2 study in Small Cell Lung CarcinomaNCT07245446 · 180 planned · China
  14. Dec 24, 2025Phase 2 study in Colorectal Cancer With Hepatic MetastasesNCT07357220 · 72 planned · China
  15. Jan 6, 2026Phase 1 study in Healthy Male SubjectsNCT07340476 · 108 enrolled · China
  16. Jun 21, 2026Phase 2 study in Advanced Non Small Cell Lung Cancer (NSCLC)NCT07669779 · 348 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT06767527
  2. Dec 2026Primary completion: phase 2 study in Solid Tumor, AdultNCT05689853
  3. Dec 30, 2026Primary completion: phase 2 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT06646055
  4. Dec 30, 2026Primary completion: phase 2 study in Triple Negative Breast NeoplasmsNCT05227664

TargetBeta

PDCD1 →VEGFA →read by rule
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tivunatamigPfizerphase 315
Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14ruleSinocelltech Groupphase 32
ABBV-1480RemeGenphase 32
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001ruleSichuan Kelun Pharmaceuticalphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010Merckphase 24
Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039AruleMinghui Pharmaceuticalphase 23
Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rulewigen-biomedicine-technology-shanghai-co-ltdphase 22
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22
Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rulecompass-therapeuticsphase 11

Studies

All 39 Akeso leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07669779Advanced Non Small Cell Lung Cancer (NSCLC) · China2RecruitingAug 30, 2027348
NCT07340476Healthy Male Subjects · China1Active, not recruitingApr 10, 2026108
NCT07357220Colorectal Cancer With Hepatic Metastases · China2Not yet recruitingFeb 28, 202772
NCT07245446Small Cell Lung Carcinoma · China2RecruitingDec 2027180
NCT07158840Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingSep 202860
NCT07114315Pancreatic Neoplasms · China2RecruitingAug 2027160
NCT07010263Small Cell Lung Carcinoma · China3RecruitingDec 31, 2028560
NCT06953999Pancreatic Neoplasms · China3RecruitingMay 14, 2027999
NCT06951503Colorectal Adenocarcinoma · China3RecruitingJan 13, 2027560
NCT06928389Carcinoma, Non-Small-Cell Lung · China3RecruitingMay 2027536
NCT06938321Biliary Tract Neoplasms · China2RecruitingMay 2027135
NCT06767527Triple Negative Breast Neoplasms · China3RecruitingDec 2026416
NCT06686030Platinum-sensitive Ovarian Cancer · China2RecruitingOct 2027150
NCT06646055Metastatic Pancreatic Ductal Adenocarcinoma · China2Active, not recruitingDec 30, 2026110
NCT06591520Biliary Tract Neoplasms · China3Active, not recruitingOct 2026682
NCT06601335Squamous Cell Carcinoma of Head and Neck · China3RecruitingJan 2027510
NCT06560112Ovarian Neoplasms · China2RecruitingMay 1, 2026172
NCT06530251Carcinoma, Hepatocellular · China2RecruitingJun 2026280
NCT05951608Advanced Solid Tumors · China2Active, not recruitingMay 1, 2026216
NCT05904379Advanced Non-small-cell Lung Cancer · China2Active, not recruitingJun 30, 2026233
NCT05846867Colorectal Neoplasms · China2Active, not recruitingMay 8, 2026170
NCT05840016Advanced Squamous Non Small Cell Lung Cancer · China3Active, not recruitingFeb 28, 2025532
NCT05689853Solid Tumor, Adult · China2RecruitingDec 202687
NCT05636267NSCLC · China2TerminatedFeb 24, 202559
NCT05499390Advanced Non-small-cell Lung Cancer · China3Active, not recruitingJan 29, 2024398
NCT05432492Carcinoma, Hepatocellular · China2CompletedApr 30, 202540
NCT05382442Colorectal Neoplasms · United States, China2Active, not recruitingMay 15, 2026254
NCT05229497Advanced Malignant Tumors · China2Active, not recruitingDec 31, 2026154
NCT05227664Triple Negative Breast Neoplasms · China2Active, not recruitingDec 30, 2026120
NCT05247684Resectable Non-small Cell Lung Cancer · China2Active, not recruitingAug 18, 202590
NCT05214482Advanced Malignant Tumors · China2CompletedNov 20, 2025154
NCT05184712Non-Squamous Non-small Cell Lung Cancer · China3Active, not recruitingMar 10, 2023322
NCT05116007SCLC, Extensive Stage · China1CompletedDec 4, 202335
NCT04999605Ovarian Neoplasms · China2TerminatedJun 10, 20228
NCT04900363Carcinoma, Non-Small-Cell Lung · China2CompletedJun 28, 2024108
NCT04870177Neoplasm Metastasis · China2CompletedMay 10, 202453
NCT04736823NSCLC · China2Active, not recruitingJul 2026265
NCT04597541Solid Tumor, Adult · China2CompletedMar 31, 202259
NCT04047290Neoplasms · Australia1CompletedFeb 27, 202480

How it is read

Names in the registry

  • “AK112”, 27 entries
  • “Ivonescimab Injection”, 3 entries
  • “Ivonescimab”, 3 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “AK112 Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.